Matinas BioPharma
MTNB
68 hedge funds and large institutions have $32M invested in Matinas BioPharma in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 5 reducing their positions, and 8 closing their positions.
440% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 5
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
6% more funds holding
Funds holding: 64 → 68 (+4)
0.18% more ownership
Funds ownership: 0.37% → 0.54% (+0.18%)
52% less capital invested
Capital invested by funds: $67.4M → $32M (-$35.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$13.6M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$3.05M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.74M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$1.56M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$454K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$251K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$180K |
| 4 |
SG Americas Securities
New York
|
-$101K |
| 5 |
IWAG
Integer Wealth Advisors Group
Cartersville,
Georgia
|
-$82K |
MTNB Hedge Fund Activity: Q1 2020 in Review
68 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2020, worth a combined $32M — down 52% from $67.4M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new MTNB positions and 8 closed out — a net gain of 6 holders — while 27 added to existing stakes and 5 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $13.6M. The largest seller was CIBC Private Wealth Group, exiting entirely with an estimated $454K sold.
- 68 institutional investors held Matinas BioPharma (MTNB) as of Q1 2020, up from 64 in Q4 2019.
- Funds reported $32M of Matinas BioPharma stock for Q1 2020, down 52% quarter-over-quarter.
- 14 funds opened new Matinas BioPharma positions in Q1 2020 and 8 closed out, a net change of +6 holders.
- The largest Matinas BioPharma buyer in Q1 2020 was Vivo Capital, an estimated $13.6M added.
- The largest Matinas BioPharma seller in Q1 2020 was CIBC Private Wealth Group, an estimated $454K sold.
Based on aggregated 13F filings for Q1 2020.